YHYulong He

Yulong He

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Yulong He has a total of 27 co-authors. Here are the top co-authors by number of shared publications:

  • Xin-Lin Chen

    School of Basic Medical Sciences Guangzhou University of Chinese Medicine Guangzhou China

    3 shared publications
  • Bin Tang

    Department of Surgery The First Affiliated Hospital Guangzhou Guangdong China

    1 shared publication
  • Bing Tang

    Center for Aortic Surgery, Beijing Anzhen Hospital of Capital Medical University, Beijing 101118, China

    1 shared publication
  • Chang-Hua Zhang

    Wei-Ling He, Shi-Rong Cai, Wu Song, Chang-Hua Zhang, Yu-Long He, Department of Gastrointestinal and Pancreatic Surgery, The First Affiliated Hospital, Sun Yat-sen University, Guangzhou 510080, Guangdong Province, China

    1 shared publication
  • Dongjie Yang

    Department of Gastrointestinal and Pancreatic Surgery, The first Affiliated Hospital of Sun Yat-Sen University, Guangzhou 510080, China

    1 shared publication
  • Li-Ya Lu

    Wei-Ling He, Shi-Rong Cai, Wu Song, Chang-Hua Zhang, Yu-Long He, Department of Gastrointestinal and Pancreatic Surgery, The First Affiliated Hospital, Sun Yat-sen University, Guangzhou 510080, Guangdong Province, China

    1 shared publication

Latest Publications

  • miR‐494 acts as an anti‐oncogene in gastric carcinoma by targeting c‐myc

    by Weiling He, Yuhuang Li, Xinlin Chen, Liya Lu, Bin Tang, Zhixiong Wang, Yunbao Pan, Shirong Cai, Yulong He, Zunfu Ke

    Background: We recently showed that miR‐494 was downregulated in gastric carcinoma (GC). The objectives of this study were to determine the role of miR‐494 in GC malignancy and to identify its target genes.Methods: Real‐time polymerase chain reaction was employed to quantify the expression level of miR‐494 and c‐myc in gastric cancer tissues. Bioinformatics was used to predict the downstream target genes of miR‐494, which were confirmed by luciferase and RNA immunoprecipitation assays. Cell functional analyses and a xenograft mouse model were used to evaluate the role of miR‐494 in malignancy.Results: miR‐494 was downregulated in human GC tissues and in GC cells and was negatively correlated with c‐myc expression. High level of c‐myc or low level of miR‐494 correlated with poor prognosis. The miR‐494‐binding site in the c‐myc 3′ untranslated region was predicted using TargetScan and was confirmed by the luciferase assay. Additionally, c‐myc and miR‐494 were enriched in coimmunoprecipitates with tagged Argonaute2 proteins in cells overexpressing miR‐494. Furthermore, a miR‐494 mimic significantly downregulated endogenous c‐myc expression, which may contribute to the delayed G1/S transition, decreased synthesis phase bromodeoxyuridine incorporation, and impaired cell growth and colony formation; on the other hand, treatment with a miR‐494 inhibitor displayed the opposite effects. Reduced tumor burden and decreased cell proliferation were observed following the delivery of miR‐494 into xenograft mice.Conclusion: miR‐494 is downregulated in human GC and acts as an anti‐oncogene by targeting c‐myc. miR‐494 plays a role in the pathogenesis of gastric cancer in a recessive fashion.


  • Open Access

    RAD51 potentiates synergistic effects of chemotherapy with PCI-24781 andcis-diamminedichloroplatinum on gastric cancer

    by Wei-Ling He, Yu-Huang Li, Wei-Jian Hou, Zun-Fu Ke, Xin-Lin Chen, Li-Ya Lu, Shi-Rong Cai, Wu Song, Chang-Hua Zhang, Yu-Long He

    AIM: To explore the efficacy of PCI-24781, a broad-spectrum, hydroxamic acid-derived histone deacetylase inhibitor, in the treatment of gastric cancer (GC). METHODS: With or without treatment of PCI-24781 and/or cis-diamminedichloroplatinum (CDDP), GC cell lines were subjected to functional analysis, including cell growth, apoptosis and clonogenic assays. Chromatin immunoprecipitation and luciferase reporter assays were used to determine the interacting molecules and the activity of the enzyme. An in vivo study was carried out in GC xenograft mice. Cell culture-based assays were represented as mean ± SD. ANOVA tests were used to assess differences across groups. All pairwise comparisons between tumor weights among treatment groups were made using the Tukey-Kramer method for multiple comparison adjustment to control experimental-wise type I error rates. Significance was set at P < 0.05. RESULTS: PCI-24781 significantly reduced the growth of the GC cells, enhanced cell apoptosis and suppressed clonogenicity, and these effects synergized with the effects of CDDP. PCI-24781 modulated the cell cycle and significantly reduced the expression of RAD51, which is related to homologous recombination. Depletion of RAD51 augmented the biological functions of PCI-24781, CDDP and the combination treatment, whereas overexpressing RAD51 had the opposite effects. Increased binding of the transcription suppressor E2F4 on the RAD51 promoter appeared to play a major role in these processes. Furthermore, significant suppression of tumor growth and weight in vivo was obtained following PCI-24781 treatment, which synergized with the anticancer effect of CDDP. CONCLUSION: These data suggest that RAD51 potentiates the synergistic effects of chemotherapy with PCI-24781 and CDDP on GC.


  • Open Access

    Double-positive expression of high-mobility group box 1 and vascular endothelial growth factor C indicates a poorer prognosis in gastric cancer patients

    by Weiling He, Bing Tang, Dongjie Yang, Yuhuang Li, Wu Song, Tuckyun Cheang, Xinlin Chen, Yin Li, Lianzhou Chen, Wenhua Zhan, et al.

    Although many studies have indicated that high-mobility group box 1 protein (HMGB1) is associated with oncogenesis and a worse prognosis, the prognostic value of HMGB1 in gastric cancer (GC) remains unclear. In the present work, we aimed to evaluate the role of HMGB1 in GC and examined whether aberrant expression of both HMGB1 and vascular endothelial growth factor C (VEGF-C) increased the malignant potential of GC. A total of 166 GC patients and 32 normal subjects were enrolled. HMGB1 and VEGF-C expression was detected by tissue microarrays (TMAs) and immunohistochemical staining. The correlation between HMGB1 and VEGF-C expression and their relationships with clinicopathological GC variables were examined. Univariate and multivariate analyses were performed using the Cox proportional hazard model to predict the factors related to the patients‘ overall survival rates. HMGB1 and VEGF-C expression were observed in 81 (48.80%) and 88 (53.01%) tumors, respectively, significantly higher than the rates among the corresponding controls. In addition, HMGB1 and VEGF-C expression were positively correlated (R2 = 0.972). HMGB1 expression was also closely associated with tumor size, pT stage, nodal status, metastasis status, TNM stage, and poor prognosis. Multivariate survival analysis indicated that patients with HMGB1 and VEGF-C coexpression had the worst prognoses and survival rates (hazard ratio, 2.78; log rank P<0.001). HMGB1 is commonly expressed in GC. Combined evaluation of HMGB1 and VEGF-C may serve as a valuable independent prognostic factor for GC patients.